[go: up one dir, main page]

MX2017014319A - Sal sodica de inhibidor de transportador de acido urico y su forma cristalina. - Google Patents

Sal sodica de inhibidor de transportador de acido urico y su forma cristalina.

Info

Publication number
MX2017014319A
MX2017014319A MX2017014319A MX2017014319A MX2017014319A MX 2017014319 A MX2017014319 A MX 2017014319A MX 2017014319 A MX2017014319 A MX 2017014319A MX 2017014319 A MX2017014319 A MX 2017014319A MX 2017014319 A MX2017014319 A MX 2017014319A
Authority
MX
Mexico
Prior art keywords
sodium salt
uric acid
acid transporter
transporter inhibitor
crystal
Prior art date
Application number
MX2017014319A
Other languages
English (en)
Other versions
MX379184B (es
Inventor
Wu Guaili
Qiu Zhenjun
SU Yunpeng
Lu Xi
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2017014319A publication Critical patent/MX2017014319A/es
Publication of MX379184B publication Critical patent/MX379184B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención se relaciona con una sal sódica de un inhibidor de transportador de ácido úrico y la forma cristalina del mismo. En particular, la presente invención se relaciona con la sal sódica de un inhibidor de transportador de ácido úrico (URAT1), el cristal tipo I y el método de preparación del mismo. La presente invención se relaciona con formato de 1-((6-bromo-quinolin-4-il)tio)ciclobutil de sodio (el compuesto de fórmula (I)), y el cristal tipo I y su método de preparación. El cristal tipo I del compuesto de fórmula (I) obtenido en la presente invención tiene buena estabilidad de forma de cristal y estabilidad química, y el solvente de cristalización utilizado tiene baja toxicidad y bajo residuo, y puede utilizarse mejor en el tratamiento clínico. (ver Fórmula).
MX2017014319A 2015-05-27 2016-05-26 Sal sodica de inhibidor de transportador de acido urico y su forma cristalina. MX379184B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510280720 2015-05-27
PCT/CN2016/083423 WO2016188444A1 (zh) 2015-05-27 2016-05-26 一种尿酸转运蛋白抑制剂的钠盐及其结晶形式

Publications (2)

Publication Number Publication Date
MX2017014319A true MX2017014319A (es) 2018-03-07
MX379184B MX379184B (es) 2025-03-10

Family

ID=57393793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014319A MX379184B (es) 2015-05-27 2016-05-26 Sal sodica de inhibidor de transportador de acido urico y su forma cristalina.

Country Status (22)

Country Link
US (2) US10196361B2 (es)
EP (1) EP3305768B1 (es)
JP (1) JP6738350B2 (es)
KR (1) KR20180006441A (es)
CN (1) CN107001276B (es)
AU (1) AU2016269359B2 (es)
BR (1) BR112017022505A2 (es)
CA (1) CA2984961C (es)
CY (1) CY1123262T1 (es)
DK (1) DK3305768T3 (es)
ES (1) ES2811325T3 (es)
HR (1) HRP20201178T1 (es)
HU (1) HUE051640T2 (es)
LT (1) LT3305768T (es)
MX (1) MX379184B (es)
PL (1) PL3305768T3 (es)
PT (1) PT3305768T (es)
RS (1) RS60749B1 (es)
RU (1) RU2719484C2 (es)
SI (1) SI3305768T1 (es)
SM (1) SMT202000421T1 (es)
WO (1) WO2016188444A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3305768T (pt) * 2015-05-27 2020-08-03 Jiangsu Hengrui Medicine Co Sal de sódio de um inibidor do transportador do ácido úrico e forma cristalina do mesmo
CN108201529B (zh) * 2016-12-16 2021-10-08 江苏恒瑞医药股份有限公司 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法
CN110467571B (zh) * 2018-05-11 2021-02-26 江苏恒瑞医药股份有限公司 一种制备环烷基甲酸类衍生物或其可药用盐的方法
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP2998296B1 (en) * 2013-05-13 2018-03-14 Shanghai Hengrui Pharmaceutical Co. Ltd. Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
PT3305768T (pt) * 2015-05-27 2020-08-03 Jiangsu Hengrui Medicine Co Sal de sódio de um inibidor do transportador do ácido úrico e forma cristalina do mesmo

Also Published As

Publication number Publication date
US10196361B2 (en) 2019-02-05
ES2811325T3 (es) 2021-03-11
CA2984961A1 (en) 2016-12-01
AU2016269359A1 (en) 2017-11-23
HRP20201178T1 (hr) 2020-11-13
CN107001276A (zh) 2017-08-01
BR112017022505A2 (pt) 2018-07-17
US20190040015A1 (en) 2019-02-07
SMT202000421T1 (it) 2020-09-10
HUE051640T2 (hu) 2021-03-01
DK3305768T3 (da) 2020-08-10
AU2016269359B2 (en) 2020-02-06
MX379184B (es) 2025-03-10
RU2017142996A3 (es) 2019-11-20
CY1123262T1 (el) 2021-12-31
EP3305768B1 (en) 2020-07-01
JP2018515454A (ja) 2018-06-14
EP3305768A1 (en) 2018-04-11
CN107001276B (zh) 2020-03-13
SI3305768T1 (sl) 2020-10-30
WO2016188444A1 (zh) 2016-12-01
PT3305768T (pt) 2020-08-03
US20180134663A1 (en) 2018-05-17
PL3305768T3 (pl) 2020-12-28
US10358424B2 (en) 2019-07-23
EP3305768A4 (en) 2019-02-13
JP6738350B2 (ja) 2020-08-12
RS60749B1 (sr) 2020-10-30
CA2984961C (en) 2023-08-01
KR20180006441A (ko) 2018-01-17
RU2017142996A (ru) 2019-06-27
LT3305768T (lt) 2020-08-25
RU2719484C2 (ru) 2020-04-17

Similar Documents

Publication Publication Date Title
BR102014006322B8 (pt) 4-amino-6-picolinatos(heterocílicos) e 6-amino-2-pirimidina-(heterocíclica)-4-carboxilatos, e processo para controle de vegetação indesejada
EA201591891A1 (ru) Пептидное соединение
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
AR098110A1 (es) Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
EA201492285A1 (ru) Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar)
EA201490747A1 (ru) 1-арилкарбонил-4-оксипиперидиновые соединения, полезные для лечения нейродегенеративных заболеваний
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
CY1123262T1 (el) Αναστολεας metaφopea aλatoς natpioy oypikoy oξeoς kai kpyσtaλλikh mopφh aytoy
AR133154A2 (es) Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable
MX2017011392A (es) P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.
WO2014128545A3 (en) An improved process for the preparation of dolutegravir
MX2020010384A (es) Proceso para la fabricacion de medicamentos.
BR112015029348A2 (pt) inibidores da bace
AR110119A1 (es) Proceso para la purificación de pirazolpiridazinas
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
UY37421A (es) Método para producir la forma cristalina de modificación a de calcobutrol
MX394399B (es) Inhibidor de urat1 para promover la excresion de acido urico.
MX2017009270A (es) Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion.
MX2017007573A (es) Composicion acuosa novedosa.
EA201790098A1 (ru) Гербицидно действующие амиды арилкарбоновых кислот
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы
EA201790522A1 (ru) Соль производного цефалоспорина, ее кристаллическое твердое вещество и способ ее получения
TW201613944A (en) Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same
BR112017005454A2 (pt) composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina